Pharming Group N.V. develops and commercializes medicines for rare and ultra-rare diseases, with news focused on RUCONEST®, Joenja® (leniolisib) for activated phosphoinositide 3-kinase delta syndrome, and the company's rare-disease pipeline. Updates commonly cover clinical studies, market authorizations, commercial launches, licensing economics, product revenue trends, and management presentations at healthcare investor conferences.
The company operates as a global biopharmaceutical issuer listed on Euronext Amsterdam and Nasdaq. Recurring coverage also includes financial results, regulatory interactions in major markets, and development programs involving small molecules, biologics, protein replacement therapies, and precision medicines for immunological and genetic conditions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.